[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346353-105":59,"doc-detail-346353-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","evaluating-murine-double-minute-2-status-as-a-stratification-tool-for-risk-adapted-management-in-plasma-cell-neoplasms-original-research-article","Evaluating murine double minute 2 status as a stratification tool for risk-adapted management in plasma cell neoplasms - Original research article","","Background: The E3 ubiquitin ligase murine double minute 2 (MDM2) negatively regulates p53 and has been linked to cancer development. In multiple myeloma (MM), elevated MDM2 expression may contribute to progression and therapy resistance, but its prognostic value assessed by immunohistochemistry (IHC) remains insufficiently established. Aim: Assess the clinical, pathological, and prognostic significance of MDM2 expression in plasma cell neoplasms for early severity and treatment-response indication.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evaluating-murine-double-minute-2-status-as-a-stratification-tool-for-risk-adapted-management-in-plasma-cell-neoplasms-original-research-article/346353/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evaluating-murine-double-minute-2-status-as-a-stratification-tool-for-risk-adapted-management-in-plasma-cell-neoplasms-original-research-article/346353.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is MDM2 and why is it relevant to plasma cell neoplasms?","Question",{"text":112,"@type":113},"MDM2 is an E3 ubiquitin ligase that acts as a negative regulator of p53. In MM, increased MDM2 expression has been associated with disease progression and resistance, motivating evaluation of its prognostic role.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was MDM2 expression measured in the study?",{"text":117,"@type":113},"The study used retrospective analysis of 71 patients, with MDM2 protein expression assessed by immunohistochemistry (IHC) on extramedullary lesion biopsy samples using the MDM2 (A.M.1) monoclonal antibody. Nuclear staining in at least 1% of plasma cells defined MDM2 positivity.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show regarding prognosis and treatment response?",{"text":121,"@type":113},"MDM2 expression was found in 30% of samples. MDM2-positive patients had significantly lower serum albumin, worse treatment responses at 12 weeks, and a markedly shorter median relapse-free survival (22 vs 68 months). Overall survival was not significantly different.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346353,1790197487,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","| W | J | C | O | World Journal of\u003Cbr>Clinical Oncology |\n| --- | --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Clin Oncol 2026 January 24; 17(1): 111426  \nDOI: 10.5306/wjco.v17.i1.111426 ISSN 2218-4333 (online)  \nORIGINAL ARTICLE  \nRetrospective Study  \nEvaluating murine double minute 2 status as a stratification tool for risk-adapted management in plasma cell neoplasms  \nNoura A A Ebrahim, Habiba Elfandy, Aya Mohamed Adel Arafat, Amira Diyaa Darwish, Mahitab Ibrahim Eltohamy  \nSpecialty type: Oncology  \nProvenance and peer review:  \nInvited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s classification Scientific Quality: Grade A, Grade B, Grade B  \nNovelty: Grade A, Grade C, Grade C  \nCreativity or Innovation: Grade A, Grade C, Grade C  \nScientific Significance: Grade B, Grade B, Grade C  \nP-Reviewer: Pant A, PhD, Researcher, United States; Zaiema SEGE, MD, Assistant Professor, Researcher, Egypt  \nReceived: July 7, 2025  \nRevised: July 29, 2025  \nAccepted: December 11, 2025  \nPublished online: January 24, 2026  \nProcessing time: 199 Days and 10 Hours  \nNoura A A Ebrahim, Habiba Elfandy, Mahitab Ibrahim Eltohamy, Department of Oncologic Pathology, National Cancer Institute, Cairo University, Cairo 11796, Al Qāhirah, Egypt  \nAya Mohamed Adel Arafat, Department of Clinical and Chemical Pathology, Kasr Al-Aini Faculty of Medicine, Cairo University, Cairo 11562, Egypt  \nAmira Diyaa Darwish, Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo 11796, Al Qāhirah, Egypt  \nCo-first authors: Noura A A Ebrahim and Habiba Elfandy.  \nCorresponding author: Noura A A Ebrahim, MD, MSc, PhD, Assistant Professor, Department of Oncologic Pathology, National Cancer Institute, Cairo University, 1st Kasr Alainy Street, Cairo 11796, Al Qāhirah, [Egypt.](Egypt. npathologist@gmail.com)[ npathologist@gmail.com](Egypt. npathologist@gmail.com)  \nAbstract  \nBACKGROUND  \nThe E3 ubiquitin ligase murine double minute 2 (MDM2) is a key negative regulator of the tumor suppressor protein p53 and has been implicated in the development of various cancers, including hematologic malignancies. In multiple myeloma (MM), increased MDM2 expression has been reported and may play a role in disease progression and resistance to therapy. Despite this, the prognostic implications of MDM2 detected through immunohistochemistry (IHC) remain insufficiently defined.  \nAIM  \nTo evaluate the clinical, pathological, and prognostic significance of MDM2 expression in plasma cell neoplasms, with a focus on its potential utility as an early indicator of disease severity and therapeutic response.  \nMETHODS  \nA retrospective analysis was conducted on 71 patients diagnosed with MM or related plasma cell disorders treated at the National Cancer Institute between 2018 and 2022. MDM2 protein expression was assessed using IHC on extramedullary lesion biopsy samples, employing the MDM2 (A.M.1) monoclonal antibody. Nuclear staining in at least 1% of plasma cells was used as the threshold for MDM2 positivity. Comparative analyses were performed between MDM2-positive and  \n [https://dx.doi.org/10.5306/wjco.v17.i1.111426](https://dx.doi.org/10.5306/wjco.v17.i1.111426) 1 January 24, 2026  Volume 17  Issue 1   \nEbrahim NAA et al. Prognostic impact of MDM2 expression  \nMDM2-negative groups, examining clinical characteristics, laboratory data, histo-pathological features, treatment responses at 12 weeks and 24 weeks, and survival outcomes, including relapse-free survival (RFS) and overall survival.  \nRESULTS  \nMDM2 expression was identified in 30% of patient samples. While no major differences were observed in baseline demographics, disease stage, or most laboratory values, serum albumin levels were significantly lower in MDM2-positive patients (P = 0.007) . At 12 weeks, patients with MDM2-positive disease showed significantly poorer treatment responses base","cbCaihHY50f9krP5","https://ap.wps.com/l/cbCaihHY50f9krP5","pdf",40043018,13,"English","# Abstract\n## Background\n## Aim\n## Methods\n## Results\n## Conclusion","[{\"question\":\"What is MDM2 and why is it relevant to plasma cell neoplasms?\",\"answer\":\"MDM2 is an E3 ubiquitin ligase that acts as a negative regulator of p53. In MM, increased MDM2 expression has been associated with disease progression and resistance, motivating evaluation of its prognostic role.\"},{\"question\":\"How was MDM2 expression measured in the study?\",\"answer\":\"The study used retrospective analysis of 71 patients, with MDM2 protein expression assessed by immunohistochemistry (IHC) on extramedullary lesion biopsy samples using the MDM2 (A.M.1) monoclonal antibody. Nuclear staining in at least 1% of plasma cells defined MDM2 positivity.\"},{\"question\":\"What did the results show regarding prognosis and treatment response?\",\"answer\":\"MDM2 expression was found in 30% of samples. MDM2-positive patients had significantly lower serum albumin, worse treatment responses at 12 weeks, and a markedly shorter median relapse-free survival (22 vs 68 months). Overall survival was not significantly different.\"}]","Evaluating murine double minute 2 status as a stratification tool for risk-adapted management in plasma cell neoplasms - Original research article | PDF",1790061042,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a10de7f7d87bd4eaff394ea2f6a3c3d8.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/67547ed29f1a8c76c5bfeb8af2e26337.webp",982,1389,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1ee78c809a0d0301d6fa5723f9f00eba.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/55d09613537aef22a8b82a1bf5d7bc32.webp",980,1386]